Arm/Leg Rest Market - Size, Share, Outlook, and Opportunity Analysis, 2026

Arm/Leg rest is a feature that is found in wheelchairs, modern vehicles, aircrafts, and auditoriums where user can rest their arms or legs and able to balance their body. Placing the weight of arms on armrest reduces downward gravity acting on the spine and helps in improving posture, maintaining the integrity of the spine and intervertebral discs. Leg rests have an adjustable angle, which are removable and have calf pads that support lower part of the leg when elevated. Such features of arm/leg rest are helpful in spinal cord injury patients.

Browse Research Report At: https://www.coherentmarketinsights.com/ongoing-insight/arm-leg-rest-market-2222

Arm/Leg Rest Market – Drivers

Research and development activities in arm/leg rest technology for the comfort of users is expected to propel growth of the arm/leg rest market. For instance, in 2018, Soarigami, developed a new, portable, and user friendly armrest device. Its stainless steel hardware adjusts to different arm widths with removable coverings and durability and facilitates its use in airplanes, trains, stadiums, and other places.

Arm/Leg Rest Market – Restraint

Difficulty in moving and height adjustment are reducing user compliance, which in turn is expected to restrain growth of the arm/leg rest market. For instance, according to report published by United Spinal Association, 2017, armrest contains movable parts, which tend to get damaged. Wheelchair armrests may also at times interfere with wheelchair propulsion, making wheels more difficult to move.

Arm/Leg Rest Market – Regional Analysis

On the basis of region, the arm/leg rest market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected hold a dominant position in the global arm/leg rest market over the forecast period. This is owing to increasing prevalence of spinal cord injuries, which further result in arm and legs disabilities. For instance, according to Spinal Cord.com statistics, 2017, around 17,500 new spinal cord injuries are registered in the U.S., annually.

Furthermore, Europe is expected to witness significant growth in the arm/leg rest market, owing to new product launches. For instance, in March 2016, Yanfeng Automotive Interiors (YFAI), a Germany-based company, developed a new heated armrest for door panels of cars. Such armrest offers comfort, flexibility, and energy efficiency during winter.

Key players operating in the arm/leg rest market include, Inmoclinc s.a, Provita medical gmbh & co. kg., KOHLAS, Bristol Maid, Medi-Plinth, Cardinal Health, General Electric Company, and Better Mobility Ltd.

Request Sample Report At: https://www.coherentmarketinsights.com/insight/request-sample/2222

Arm/Leg Rest Market – Taxonomy

By Application

• Arm Support
• Leg Support

By End User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Home Care Settings
• Rehabilitation Centers

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Blood Banking Devices Market to surpass US$ 49.8 billion by 2026

The Global Blood Banking Devices Market, by Product Type (Blood Collection Devices (Blood Collection Needles, Blood Collection Tubes (Serum Collection Tubes, Plasma Collection Tubes, Heparin Tubes, and Other Tubes), Needles & Syringes, Lancets, Vacuum Blood Collection System, Blood Bags, and Accessories), Blood Processing Devices (Blood Grouping Analyzers, Blood Cell Processors, Blood Filters, Centrifuges, and Others), and Blood Storage Devices (Blood Bank Refrigerators and Blood Bank Freezers)), by Method of Collection (Manual Blood Collection and Automated Blood Collection), End User (Blood Banks, Hospitals and Other End Users), and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued US$ 28.1 billion in 2018 and is projected to exhibit a CAGR of 7.4% over the forecast period (2018 - 2026), as highlighted in a new report published by Coherent Market Insights.

Key players operating in the market are adopting strategies such as mergers and acquisitions to gain competitive edge in the blood banking devices market. For instance, in January 2017, Hologic, Inc. completed the divestiture of its blood screening business to Grifols for deal value of US$ 1.85 billion. This divestment will help Hologic to significantly accelerate their financial flexibility.

Download And Get Sample PDF File Of Blood Banking Devices Industry: https://www.coherentmarketinsights.com/insight/request-sample/1980

In January 2017, Werfen and its subsidiary Instrumentation Laboratory (IL) announced the acquisition of Accriva Diagnostics, a company engaged in in-vitro diagnostic (IVD) blood testing at the point-of-care (POC), including their innovative product portfolio spanning coagulation, platelet aggregation, CO-Oximetry, and incision devices.

Furthermore, in September 2016, Instrumentation Laboratory (IL) announced the acquisition of CA Casyso AG and its Tem subsidiaries, a company engaged in in-vitro diagnostic (IVD) testing for Patient Blood Management (PBM) with their ROTEM testing systems.

Key players in the blood banking devices market are engaged in developing innovative strategies such as mobile van blood banking, robotic blood collection system, and blood banking mobile app to enable easy access to donors, which is expected to show lucrative revenue growth over the forecast period.

For instance, in May 2017, Poly Medicure Ltd., manufacturer of medical devices in India, launched their blood banking products in the Indian local market (Haryana), thereby expanding their geographical presence in the local market.

Moreover, in January 2017, Social Capital, an NGO from Coimbatore, India launched an android app for blood donation, with support from the Coimbatore Corporation and Sri Ramakrishna Multi-specialty Hospital. Furthermore, this app will help hospitals and blood banks to connect with donors. In September 2014, the American Red Cross launched a blood donor app, which made it easier for people to track their blood donations and schedule for new ones.

In April 2018, Immucor, Inc., a leader in transfusion and transplantation diagnostics, received the U.S. Food and Drug Administration (FDA) approval for their fully automated Echo instrument called as Echo Lumena. Echo Lumena is Immucor’s fifth generation immunohematology instrument, which offers faster and clearer blood compatibility result.

Browse 30 Market Data Tables and 35 Figures spread through 182 Pages and in-depth TOC on ‘Blood Banking Devices Market, by Product Type (Blood Collection Devices (Blood Collection Needles, Blood Collection Tubes (Serum Collection Tubes, Plasma Collection Tubes, Heparin Tubes, and Other Tubes), Needles & Syringes, Lancets, Vacuum Blood Collection System, Blood Bags, Accessories), Blood Processing Devices (Blood Grouping Analyzers, Blood Cell Processors, Blood Filters, Centrifuges, and Others), and Blood Storage Devices (Blood Bank Refrigerators and Blood Bank Freezers)), by Method of Collection (Manual Blood Collection and Automated Blood Collection), End User (Blood Banks, Hospitals and Other End Users), and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa - Global Forecast to 2026’

To know the latest trends and insights related to blood banking devices market, click the link below: https://www.coherentmarketinsights.com/market-insight/blood-banking-devices-market-1980

Key takeaways of the Blood Banking Devices Market:

• The global blood banking devices market is expected to expand at a CAGR of 7.4% during the forecast period (2018 – 2026), owing to increasing demand for blood and blood related components
• Among product type, blood collection devices segment accounted to register largest market share in product type segment, owing to increasing demand for these devices and necessity of these devices in blood component analysis at fully automated blood banks and large blood donation centers
• Among method of collection, manual blood collection segment holds a major market share. Manual blood collection systems are an easily accessible way for blood collection, which augment the market share during the forecast period. However, due to continuous advancements in blood banking associated devices, automated blood collection is expected to show higher growth rate in the near future.
• Among the End User segment, blood banks accounted to hold higher market share during forecast period, owing to their increased ability to offer large variety of blood units to associated hospitals and clinics and their ability to handle extensive amount of blood derived components, further processing and storage, for an extended period.
• Some of the major players operating in the global blood banking devices market include Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Abbott Laboratories, Fresenius Kabi AG, Beckman Coulter Inc. (Danaher Corporation), bioMérieux, Inc., China Biologic Products Holdings, Inc., Immucor, Inc.(IVD Holdings, Inc.), Instrumentation Laboratory Company, and F. Hoffmann-La Roche AG (Roche Molecular Systems Inc.).

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Axillary Crutches Market - Latest Advancements & Market Outlook 2018 to 2026

Axillary crutches are the mobility aids used by individuals suffering from walking disability, factures, paralysis, and leg injuries. Axillary crutches transfer the weight from legs to the arms/shoulders and support the movement of individuals who are unable to walk due to some disability. Axillary crutches are lightweight and they are available in various materials, which includes aluminum, stainless steel, and wooden. Axillary crutches are adjustable in size and can be adjusted as per the user need, height, and comfort. Furthermore, key players in the market are involved in developing various axillary crutches with new designs to provide comfort to its users.

To get holistic SAMPLE of the report including table of contents: https://www.coherentmarketinsights.com/insight/request-sample/2008

Axillary Crutches Market Drivers

Increasing prevalence of walking disability is expected to increase demand for axillary crutches and fuel axillary crutches market growth over the forecast period. According to Center for Disease Control and Prevention (CDC), in 2017, an estimated 8.2 million adults were suffering from some kind of walking disability in the U.S.

According to the data published by U.S. Census Bureau in 2012, approximately 30.6 million people in the U.S. has difficulty walking or climbing stairs and they require supportive medical device such as crutches and cane while waking. Such high prevalence of disabilities among population is expected to propel demand for axillary crutches in market.

Majority of the geriatric population experience some problem in walking, which require support such as axillary crutches while walking. Hence, increasing prevalence of geriatric population is expected to increase demand for axillary crutches, which in turn is expected to fuel global axillary crutches market growth over forecast period.

For instance, according to the data published by United Nations Population Fund, people aged 60 years and above accounted for 12.3% of the global population in 2015, which is expected to increase to 22% by 2050, accounting for 2 billion people. According to a survey conducted by Population Reference Bureau in 2016, over 46 million senior citizens were reported of age 65 and above in the U.S. Around 48% of this aging population is disabled due to age factor and chronic diseases.

Furthermore, increasing incidence of road accidents leading to various injuries including severe injuries in legs or permanent disability of legs is increasing the demand for axillary crutches, which in turn is expected to fuel axillary crutches market growth. For instance, according to World Health Organization (WHO), in 2017, around 1.25 million people die annually and more than 20 to 50 million people experience severe injuries and factures, due to road traffic crash.

Axillary Crutches Market Regional Analysis

North America is expected to hold a dominant position in global axillary crutches market, owing to presence of key players in region and rapid research and development activities for the development of new axillary crutches with novel design, shape, which make walking more easy and painless. For instance, in 2016, Mobility Designed, LLC, a U.S-based company, designed a novel axillary crutch with a reinvented design, which places body weight on the forearms and provides a painless walk with crutch.

Asia Pacific axillary crutches market is expected to witness significant growth owing to increasing geriatric population, which is expected to increase demand for axillary crutches in the aged people suffering from walking disability. For instance, according to the data published by United Nations Economic and Social Commission for Asia and the Pacific (ESCAP) in 2016, Asia Pacific region constitutes around 60% of the world’s geriatric population. It is estimated that in 2016, around 547 million people were aged above 60 years in Asia Pacific region and this number is expected to double and reach around 1.3 billion by 2050.

Axillary Crutches Market Restraint

Presence of alternative devices to axillary crutches is expected to be one of the major factor restraining the axillary crutches market growth over the forecast period. For instance, presence of other walking assisted device such as canes, walkers, and wheelchairs can replace the use of axillary crutches and hinder market growth.

Click to Continue Reading on Axillary Crutches Market

Axillary Crutches Market Key Players

Key players operating in global axillary crutches market include: Cardinal Health, Inc., Ossenberg GmbH, Invacare Corporation, Millennial Medical, LLC, NOVA Medical Products, Carex Health Brands Inc., GF Health Products, Inc., MIKIRAD Grzegorz Kicior, and Ergoactives.

Axillary Crutches Market Taxonomy:

The global axillary crutches market is segmented on the basis of material type, age group, and region

By Material Type-

• Aluminum
• Stainless Steel
• Wooden
• Others

By Age Group-

• Adult
• Pediatrics

By Region-

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Acute Heart Failure Therapeutics Market: Drivers, Regional Analysis, and Competitive Landscape 2026

Acute heart failure (AHF) is a progressive condition, in which, the heart muscle is unable to pump enough blood through the heart to meet body’ optimal blood and oxygen level. Congestive heart failure is type of heart failure which requires timely medical attention. Moreover, distinguish between acute and chronic heart failure is important from a clinical standpoint, on which further medication depends. For this, N terminal proB-type natriuretic peptide levels are used for distinguishing acute versus chronic left ventricular dysfunction. An elevated levels of natriuretic peptide were present in patients with acute heart failure compared to those with chronic heart failure patient.

Heart failure symptoms vary widely from person to person, depending on types of heart failure patient. The main symptoms of heart failure are caused due to fluid accumulation or congestion and poor blood flow to the body. Symptoms caused by fluid accumulation or congestion includes shortness of breath, weight gain, coughing, swollen ankles, legs or abdomen, while dizziness, rapid heart rate, and fatigue are symptoms associated with reduced blood flow to parts of the body.

Request to download and view Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/1910

Acute Heart Failure (AHF) Therapeutics Market Drivers

The global acute heart failure therapeutics market is expected to witness significant growth due to approval of new drugs. For instance, in July 2015, Novartis received U.S. Food and Drug Administration (FDA) approval for their Entresto(TM) (sacubitril/valsartan) tablets on the treatment of heart failure with reduced ejection fraction. Entresto is indicated to reduce the risk of cardiovascular death and heart failure hospitalization.

Furthermore, robust pipeline of drugs over the forecast period (2018-2026), is another factor driving growth of acute heart failure therapeutics market. For instance, in March 2017, Cardioxyl Pharmaceuticals’ CXL-1427: a novel nitroxyl (HNO) donor (prodrug), which now operates under the Bristol-Myers Squibb Company (after Cardioxyl Pharmaceuticals’ acquisition by Bristol-Myers Squibb in December 2015); is present in Phase 2 clinical development phase. CXL-1427 is indicated to use as an intravenous treatment for acute decompensated heart failure (ADHF). Successful completion and further launch of Bristol-Myers Squibb’s innovative drug in future, will help to boost the acute heart failure (AHF) therapeutics market growth during the forecast period.

Various lifestyle factors are responsible to increase risk heart attack and stroke, which includes smoking, overweight, eating foods with high fat and cholesterol, and physical inactivity. Furthermore, patients suffering with heart failure are at high risk to one or more conditions such as coronary artery disease, myocardial infraction, high blood pressure or hypertension, abnormal heart valves, dilated cardiomyopathy, hypertrophic cardiomyopathy, severe lung disease, obesity, and sleep apnea, among others. For instance, according to the World Health Organization (WHO), October 2017 data findings, in 2016, over 1.9 billion adults, were overweight, worldwide. Among which over 650 million were obese. Moreover, according to the same source, raised BMI index, owing to overweight and obesity are the major risk factors for cardiovascular disease, which was the leading cause of death in 2012, worldwide.

Acute Heart Failure (AHF) Therapeutics Market Restraints

Acute heart failure is a common condition associated with considerable morbidity, mortality, and cost. However, evidence-based data on treating heart failure in the acute setting are limited, and current individual treatment options have variable efficacy. Furthermore, healthcare team often need to customize patient care in acute heart failure treatment. For instance, dyspnea is the most common symptom associated with AHF patients. However, this symptom is non-specific as other medical conditions are commonly associated with dyspnea, including pneumonia, exacerbations of chronic obstructive pulmonary disease, pulmonary embolism, acute coronary syndrome, and asthma. This is another factor negatively affecting growth of the acute heart failure (AHF) therapeutics market.

Acute Heart Failure (AHF) Therapeutics Market – Regional Analysis

Geographically, the market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America is expected to hold dominant position in global acute heart failure (AHF) therapeutics market, due to high prevalence of acute heart failure cases, in this region. For instance, according to Centers for Disease Control and Prevention (CDC), June 2016, around 5.7 million adults in the U.S. suffered from heart failure, in 2016. Moreover, about half of the people who develop heart failure die within 5 years of diagnosis.

Furthermore, growing prevalence of obesity have increased risk of developing acute heart failure (AHF). According to CDC, May 2017 data findings, between 2013 and 2014, 37.9% of adults aged 20 years and over were obese, in the U.S. Therefore, high prevalence of risk factors and acute heart failure (AHF) cases in these region are expected to drive growth of this market over the forecast period.

Asia Pacific acute heart failure (AHF) therapeutics market is projected to witness significant growth, due to increasing focus of healthcare organizations in creating awareness regarding increasing risk factors of acute heart failure. For instance, in June 2016, Fortis Hospital, India launched Fortis Heart Rhythm and Heart failure Centre in Bangalore, to increase awareness among people regarding heart failure, stroke, and various other cardiovascular disease.

Browse Research Report At: https://www.coherentmarketinsights.com/ongoing-insight/acute-heart-failure-ahf-therapeutics-market-1910

Acute Heart Failure (AHF) Therapeutics Market – Competitive Landscape

Some of the key players in this market are Novartis AG, Cardiorentis AG, Bristol-Myers Squibb Company, Amgen Inc., Bayer AG, Cytokinetics, Inc., Merck & Company, Inc., Ono Pharmaceutical Co., Ltd., and Pfizer Inc., among others. Key players in the marker are engaged in development of new drugs for acute heart failure (AHF). These players are incorporating collaboration strategies to remain competitive in the market.

For instance, in October 2015, Cardiorentis AG announced plans to collaborate with Roche to establish therapeutic efficacy and safety of Ularitide: Cardiorentis’ investigational drug for acute heart failure (AHF). Under the terms of collaboration, Cardiorentis will incorporate Roche's advanced in vitro diagnostic tests into its TRUE-AHF Phase III study to characterize the pharmacological properties of Ularitide, evaluate its benefit-risk profile, and the appropriate clinical application in patients.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Human Growth Hormone Market: Drivers, Regional Analysis, and Competitive Landscape 2026

Human body naturally produces growth hormones in the pituitary gland. Human growth hormone is a peptide hormone, which stimulates growth, cell reproduction, and cell regeneration in humans as well as animals. Growth hormone is stored and secreted by somatotropic cells within the lateral wings of anterior pituitary gland. Functions of growth hormones include increased height during childhood, increases calcium retention, strengthens and increases mineralization of the bone, increases muscle mass through sarcomere hypertrophy, promotes lipolysis, increases protein synthesis, stimulates growth of all internal organs excluding the brain, plays a vital role in homeostasis, reduces uptake of glucose by liver, stimulates the immune system, and increases DE iodination of T4 to T3. Excess secretion of growth hormones causes pituitary tumor, which consists of somatotroph cells of the anterior pituitary. These somatotroph cells are benign and grow slowly, producing excess of growth hormones. This causes headaches, impaired vision by pressure caused on optic nerves, deficiency of other hormones secreted by pituitary gland, and thickening the bones of jaw, toes, and fingers, which eventually results in heaviness of jaws and increase in size of digits called as acromegaly. Acromegaly causes pressure on nerves, muscle weakness, and reduced sexual function. The deficiency of growth hormone causes failure in growth, increase in osteoclast activities, weakening of bones, trauma, increase in fat mass, and decrease in muscle mass.

Get PDF Research Brochure for more Professional and Technical Insights: https://www.coherentmarketinsights.com/insight/request-pdf/1859

Human Growth Hormone Market Drivers:-

Major driver for human growth hormone market is new mergers and acquisitions. For instance, in 2014, Pfizer Inc., a U.S.-based pharmaceutical company, merged with OPKO Health Inc., a U.S.-based company, to develop a long acting growth hormone (hGH-CTP) and to bring innovative treatments for growth hormone deficient patients. hGH-CTP is more convenient, as the patients need to take just one injection in a week rather than daily doses. hGH-CTP has an orphan drug designation in the U.S. and Europe for adults and children with growth hormone deficiency.

Robust pipeline is also expected to support the growth in human growth hormone market size. For instance, Somapacitan sponsored by Novo Nordisk A/S, a Denmark-based company, completed phase 3 clinical trials in 2017. This drug is used for the treatment of growth hormone deficiency in adults. MOD-4023 sponsored by Opko Biologics, an Israel-based company, completed phase 2 clinical trials in 2015. High prevalence of growth hormone deficiency is another factor boosting growth of human growth hormone market. According to a survey conducted by the National Organization for Rare Diseases (NORA) in 2015, over 10,000 children and 50,000 adults have growth hormone deficiency in the U.S.

However, strict rules and regulations for the use of human growth hormone by athletes and sports professionals is expected to restrain growth of human growth hormone market. The Food and Drug Administration (FDA) and the International Olympic Committee had banned the use of human growth hormone for sports professionals in 2006.

Human Growth Hormone Market Regional Analysis:-

North America is expected to hold dominant position in the global human growth hormone market due to new biosimilar approvals by Health Canada for biosimilar of human growth hormone drugs. For instance, in 2015, Health Canada approved the first generic biological called as PROmnitrope. PROmnitrope is a recombinant human growth hormone used to treat deficiency of growth hormone in adults as well as children. This can encourage new generic version of drugs, thereby fueling the human growth hormone market growth.

Europe human growth hormone market is expected to witness significant growth due to mergers and acquisitions. For instance, in 2017, Ferring Pharmaceuticals S.A., a pharmaceutical company, acquired a product i.e. Zoma Jet of Antares Pharma Inc, a pharmaceutical company. Zoma Jet is a needle free auto injectable device. Ferring Pharmaceuticals S.A acquired Zoma Jet in order to increase use of Zomacton (Injectable somatropin hGH). Zoma Jet is used to deliver Zomacton for the treatment of growth hormone deficiency in children and Turner’s syndrome in girls. By acquiring the injectable device Zoma Jet, would eventually lead to increase in use of the drug, Zomacton, which will further encourage Ferring Pharmaceuticals to develop better treatment options for growth hormone deficiency, thereby resulting in growth of the human growth hormone market. Asia Pacific is expected to grow over the forecast period due to robust pipeline. For instance, Cinna Tropin sponsored by Cinnagen, an Iran-based company, completed phase 3 clinical trials in 2017. This drug is used to treat idiopathic short stature in children and adults.

Click to Continue Reading on Human Growth Hormone Market

Human Growth Hormone Market Key Players:-

Key players operating in the global human growth hormone market include Pfizer Inc., Genetech Inc., Merck & Co., Eli Lilly And Company, Novo Nordisk, Sandoz International GmbH, Ferring Holding SA, and Ipsen.

Human Growth Hormone Market Taxonomy:-

By Application

• Growth Hormone Deficiency
• Idiopathic short stature
• Prader-Willi Syndrome
• Turner Syndrome
• Others

By Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Intramuscular

By Distribution Channel

• Hospitals
• Retail Pharmacies
• Online Pharmacies

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Electric Wheelchair Market: Drivers, Regional Analysis, and Competitive Landscape 2026

An electric wheelchair is a wheelchair that uses electric motor rather than manual power for functioning. Electric wheelchairs are useful for those who cannot use manual wheelchairs or who need to use wheelchairs for considerable long distance. These can be usually used by people who are physically challenged and also senior citizens with problems related to mobility. Design of a wheelchair consists of the following elements: battery, drive system, controller, and seat. The electric motors of these chairs are usually powered by 12-80 ampere per hour of rechargeable deep-cycle batteries. Some users are not able to use hand controllers and therefore, various other options are made available, for instance, sip and puff controllers, which works by blowing into the sensor. Electric wheelchair can also be used by people suffering from diseases such as chronic diseases and asthma. Electric wheelchair offers special features such as tilting capabilities, elevation of seats, and leg elevation. Electric wheelchair can also be dissembled and folded to take it around wherever needed. These are light in weight i.e. less than 100 lbs, and are also compact in size, which is ideal for narrow doorways and small spaces.

Get PDF Research Brochure for more Professional and Technical Insights: https://www.coherentmarketinsights.com/insight/request-sample/1758

Electric Wheelchair Market Drivers:-

Growth of the electric wheelchair market is driver by increasing launches of new products with advanced technologies such as automatic folding wheelchair. For instance, in June 2018, Quantum Rehab launched Edge 3, the most advanced power chair, with an upgraded SRS (Smooth Ride Suspension). SRS provides stability, comfortable, and smooth ride. Its standard features include USB charger, drive wheel color accents, and front and rear fender lights. In 2017, Ivacare Corporation, a U.S.-based company, launched TDX-SP2 ELECTRIC WHEELCHAIR. This electric wheel chair has LiNX technology and advanced positioning. LiNX technology electronic system includes wireless programming and remote monitoring, which enables better clinical evaluations and touch screen display. This technology also enables easy intuitive programming and also hassle free functioning of the equipment for its customers. Other factors, which are expected to boost growth of the electric wheelchair market are rising geriatric population, rising awareness related to benefits of use of automated wheelchairs over manual wheelchairs, and increasing prevalence of chronic disorders in geriatric population. According to a survey conducted by Population Reference Bureau in 2016, there were over 46 million senior citizens of the age 65 and above in  U.S. About 48% of this aging population are disabled due to age factor and chronic diseases. According to a survey conducted by the U.S. Census Bureau in 2017, around 40 million people in the U.S. are physically challenged. Moreover, according to a survey conducted by Center for Disease Control and Prevention in 2016, over 117 million people were diagnosed with chronic disorders. All these factors are expected to support growth of the electric wheelchair market over the forecast period (2018-2026).

Electric Wheelchair Market Regional Analysis:-

North America is expected to hold dominant position in the global electric wheelchair market, and is also expected to exhibit a significant growth rate, owing to increasing launches of novel products in the market. For instance, in April 2018, Quantum Rehab, a U.S.-based company, launched Kozmo and Kozmo Portable. This device is especially made for children. The size of Kozmo Portable electric wheelchair is compact and easy to carry. It helps in fast transport and is convenient for parents and children. Moreover, in April 2018, Quantum Rehab launched products including TRU-BALANCE 3 and TRU- BALANCE FLEX. Such new range of products is expected to fuel growth of the electric wheelchair market. Furthermore, Medicare, national (U.S.) health insurance program provides reimbursements on buying an electric wheel chair. The patient pays 20% of the amount mentioned for a given product and Medicare pays the remaining 80%. Such reimbursement plans can boost adoption of the electric wheel chair market in North America.

Click to Continue Reading on Electric Wheelchair Market

Asia Pacific is also expected to witness high growth in the global electric wheel chair market, due to rise of chronic diseases in geriatric population and increasing launch of electric wheel chairs with advanced technology. According to a survey conducted by National Institutes of health in 2015, cardiovascular disease is rising in Asian population. Cardiovascular disease has caused approximately 52% of deaths in India.  For instance, in 2017, Whill Inc., a Japan-based company, launched Model M. This device has omni-wheel technology, which can be used on rough terrain. It also has a compact size and its agile steering can easily navigate in narrow and tight spaces. Such innovations are expected to fuel growth of the electric wheelchair market.

Electric Wheelchair Market Key Players:-

Key players are operating in the electric wheelchair market are Drive Medical Ltd., Permobil AB, Quantum Rehab, GF Health Products Inc., Invacare Corporation, Karman Healthcare, Pride Mobility Products Corp, LEVO Ag, MEYRA GmbH, OttoBock Healthcare GmbH, Whill Inc., and Sunrise Medical Limited.

Electric Wheelchair Market Taxonomy:- 

By Product Type:-

• Rear Wheel Drive
• Front Wheel Drive
• Center Wheel Drive
• Standing Electric Wheelchair

By End Users:-

• Home Care Settings
• Hospitals/ Clinics
• Others

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Picture Archiving and Communication System Market to Reach Beyond US$ 3 Billion by 2025

The Global Picture Archiving and Communication System (PACS) Market, by Deployment (Web Based, Cloud Based and On Premise), by Product (Mid End PACS, Enterprise PACS and Mini PACS), by End User (Hospitals, Clinics, Diagnostics Centers and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 1.7 billion in 2017 and is projected to exhibit a CAGR of 5.5% over the forecast period (2018 – 2026), as highlighted in a new report published by Coherent Market Insights. The Picture Archiving and Communication System (PACS) market is expected to gain significant traction, due to increasing demand for healthcare IT platforms.

Request a sample to stay abreast on the key trends impacting this market: https://www.coherentmarketinsights.com/insight/request-sample/1872

Increasing demand for healthcare IT is expected to drive growth of the market

Improvements in the healthcare IT field, such as the introduction of PACS and cloud computing have provided a new prospect to the healthcare providers and hospital to improve patient centricity by boosting operational efficiencies. Various government initiatives to promote electronic data sharing and EHR adoption will allow healthcare providers to improve the clinical outcomes, with streamlining workflow. In 2009, Health Information Technology for Economic and Clinical Health (HITECH) Act, has provided over US$ 35billion incentives to expand and encourage the adoption and use of EHRs by health care professionals and hospitals. Moreover, increase in the competition among hospitals has made it necessary for management to take appropriate measures increase their efficiency with the integration of these systems at all levels.

Furthermore, the rapidly mounting geriatric population base is demanding healthcare information systems such as PACS to meet the medical requirements. According to a NIH report, in 2015, 8.5% of people were aged 65 and over. This percentage is expected to reach around 17% of the world’s population by 2050. Moreover, healthcare IT companies are continuously funding the development of new and advanced solutions. The advent of these solutions is, thus, providing growth opportunities in PACS market.

Key players are focusing on new product launches and improvements in existing ones in order to accelerate business growth. For instance, in June, 2015, Ricoh India, a leader in the field of Imaging Solutions, launched its fully integrated cloud-enabled PACS solution ‘Picasso’. This new solution will provide access of medical images to clinicians and patients, along with reducing the cost of providing medical care. In 2017, FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging and medical informatics products, launched version 5 of Synapse PACS in the U.S. Synapse 5 is one component of Fujifilm’s comprehensive enterprise imaging portfolio which includes RIS, 3D, Cardiovascular, Enterprise Viewer, Synapse VNA, and cloud services.

Browse 39 Market Data Tables and 28 Figures spread through 180 Pages and in-depth TOC on “Picture Archiving and Communication System (PACS) Market, by Deployment (Web Based, Cloud Based and On Premise), by Product (Mid End PACS, Enterprise PACS and Mini PACS), by End User (Hospitals, Clinics, Diagnostics Imaging Centers and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026”

To know the latest trends and insights prevalent in the Picture Archiving and Communication System (PACS) market, click the link below: https://www.coherentmarketinsights.com/market-insight/picture-archiving-and-communication-system-pacs-market-1872

Key Takeaways of the Picture Archiving and Communication System (PACS) Market:

• The global picture archiving and communication system (PACS) market is expected to exhibit a CAGR of 5.5% over the forecast period, owing to increasing adoption of health IT among healthcare providers.
• Among deployment, the cloud based segment holds a dominant position in the picture archiving and communication system (PACS) market, owing to more imaging modalities demanding cloud-based PACS.
• Among product, the mid end PACS segment holds a dominant position in the picture archiving and communication system (PACS) market, owing to increase in adoption rate and growing demand for integrated solutions Among end user, hospitals segment holds a dominant position in the picture archiving and communication system (PACS) market, owing to increased usage in hospitals for imaging.
• North America picture archiving and communication system (PACS) market is expected to exhibit significant growth, owing to large number of hospitals and imaging centers using imaging techniques.
• Key players operating in the global picture archiving and communication system (PACS) market include Agfa-Gevaert Group, Carestream Health, FUJIFILM Medical Systems, INFINITT Healthcare Co. Ltd., GE Healthcare, Koninklijke Philips N.V., Merge Healthcare Solutions Inc., Mckesson Corp., Sectra AB and Siemens Healthineers.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Specialty Injectable Generics Market Clinical Review, Drug Descriptions, Analysis and Synthesis 2026

Specialty injections are high cost medications or drugs that are used to treat various complex diseases such as cancer, HIV, rheumatoid arthritis, hemophilia, and central nervous system diseases. Specialty injections are often biologics that are produced by biotechnology methods. Specialty drugs are complex to manufacture. Some specialty injectable can be self-administered.

Specialty drugs may also be defined as orphan or ultra-orphan drugs under the U.S. Orphan drug act 1983. This was enacted to facilitate development of orphan drugs, which are drugs for rare diseases such as Huntington’s disease, muscular dystrophy, amyotrophic lateral sclerosis, and myoclonus.

Request a sample to stay abreast on the key trends impacting this market: https://www.coherentmarketinsights.com/insight/request-sample/1877

Specialty Injectable Generics Market Drivers:

New product launches are expected to be a major driver for growth of the specialty injectable generics market. For instance, in 2015, Avatis Plc., a global specialty pharmaceutical company, launched specialty generic injections portfolio. This portfolio includes generic versions of Gemzar, Campostar, Taxotere, and Zometa, which are used for the treatment of cancer.

In 2016, Teva Pharmaceuticals Industries Ltd. launched generic equivalent to Imitrex 1 (sumatriptan) injection, 4mg and 6mg single-dose. Sumatriptan is used in the treatment of acute migraines and acute cluster headaches in adults. Sumatriptan injection can be self-administered subcutaneously into the outer thigh or an arm.

Mergers and acquisitions are also expected to boost growth of the specialty injectable generics market size. For instance, in 2014, Sagent Pharmaceuticals Inc., a specialty pharmaceutical company, acquired Omega Laboratories Ltd., a specialty pharmaceutical company, to develop and enhance their specialty injectable portfolio.

In 2015, Endo International Plc., a generic and specialty pharmaceutical company, acquired Par pharmaceutical companies Inc., which markets, develops, and distributes generic drugs in the U.S., to develop and enhance its generic injectable drugs portfolio and to double the revenue generated by its generic division.

Prevalence of diseases such as cancer, central nervous system disorders, and chronic diseases are also expected to drive the specialty injectable generics market growth. According to a survey conducted by the National Institute of Health in 2018, there are over 23,880 new cancer cases in the U.S.

Click to Continue Reading on Specialty Injectable Generics Market

Restraints of specialty injectable generics market include high cost of medications, which is required over a long period of time. For instance, 1g Gemzar (gemcitabine) indicated for the treatment costs around US$ 800 in the U.S. and the price varies with region. Therefore, high cost of medications severely limits the adoption rate.

Specialty Injectable Generics Market Regional Analysis:

North America is expected to hold dominant position in the global specialty injectable generics market due to mergers and acquisitions. For instance, in May 2018, Impax Laboratories Inc. partnered with Amneal Pharmaceuticals Inc., a specialty pharmaceutical company to develop affordable and more accessible specialty injectable generics. This will lead to the development of new injectable generics for the treatment of various diseases.

New product launches are also expected to boost North America specialty injectable generics market growth. In March 2018, Teva pharmaceutical Industries Ltd. launched generic version of Aloxi injection 0.25mg/5ml called as Palonosetron hydrochloride injection in the U.S. market.

Europe is expected to witness growth owing to rising number of cancer patients. According to a study conducted by the World Health Organization (WHO) in 2016, over 753,600 people were diagnosed with cancer in this region.

Asia Pacific specialty injectable generics market is expected to witness significant growth over the forecast period owing to new product launches. For instance, in June 2018, Dr. Reddy’s Laboratories, an Indian pharmaceutical company, launched specialty generic injection Levetiracetram in sodium chloride injection, which is a generic version of HQ Specialty Pharma Corporation’s Levetiracetram in sodium chloride injection.

Mergers and acquisitions is also expected to fuel growth of the market in this region. In 2017, Lupin Ltd. acquired Symbiomix Therapeutics LLC., a pharmaceutical company, to develop and expand in women health segment.

Specialty Injectable Generics Market Key Players:

Key players operating in this market include Pfizer Inc., Mylan N.V., Teva Pharmaceuticals Industries Ltd., Fresenius SE & Co. KGaA, and Hikma Pharmaceuticals Plc. New product launches by key players is expected to drive the specialty injectable generics market growth. For instance, in 2017, Mylan N.V., a global generic and specialty pharmaceuticals company, launched the generic version of Pfizer’s Cerebryx, which is an injectable variety of fasphenytoin sodium.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Human Recombinant Insulin Market to surpass US$ 47.8 billion by 2026: CMI

The Global Human Recombinant Insulin Market, by Product Type (Rapid-Acting Human Insulin, Short-Acting Human Insulin, Intermediate-Acting Human Insulin, Long-Acting Human Insulin, and Premixed Human Insulin), by Brand (Humalog, Novolog, Apidra, Humulin R, Novolin R, Humulin N, Novolin N, Levemir, Lantus, Humalog Mix, Novolog Mix, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) was valued US$ 27.4 billion in 2018, and is projected to exhibit a CAGR of 7.2% over the forecast period (2018 - 2026) as highlighted in a new report published by Coherent Market Insights.

Browse 35 Market Data Tables and 42 Figures spread through 205 Pages and in-depth TOC on "Human Recombinant Insulin Market, by Product Type (Rapid-Acting Human Insulin, Short-Acting Human Insulin, Intermediate-Acting Human Insulin, Long-Acting Human Insulin, and Premixed Human Insulin), by Brand (Humalog, Novolog, Apidra, Humulin R, Novolin R, Humulin N, Novolin N, Levemir, Lantus, Humalog Mix, Novolog Mix, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Forecast to 2026"

To know the latest trends and insights related to human recombinant insulin market, click the link below: https://www.coherentmarketinsights.com/market-insight/human-recombinant-insulin-market-1797

Key manufacturers are engaged in launching novel human insulin portfolio and gaining regulatory approval for their insulin product portfolio. For instance, in August 2014, Eli Lilly and Company launched Jardiance (empagliflozin) as a treatment option for Type 2 diabetes patients in the U.S. Jardiance is a sodium glucose co-transporter-2 (SGLT2) inhibitor with Type 2 diabetes patients. In March 2016, Biocon Limited collaborated with LaboratoriosPiSA S.A de CV (PiSA) to jointly develop and sell a generic recombinant human insulin in America. Biocon expects the product to launch by 2020 in the U.S. In February 2018, Novo Nordisk launched Fiaspa: a fast-acting mealtime insulin in the U.S. Fiaspa received U.S. FDA approval and indicated to improve glycemic control in adults with type 1 and type 2 diabetes. In December 2017, the U.S. Food and Drug Administration (FDA) approved Sanofi’s Admelog. Admelog is a follow-on mealtime insulin, which helps people living with diabetes manage blood sugar levels at mealtime.

Efficient diabetes management and ease of use creates need for advancements in current solutions of both insulin and its delivery systems thereby, offering reduced patient discomfort. Glucose Responsive Insulin (GRI) or smart insulin is a novel technology for people with diabetes, which works by automatically reacting to blood sugar fluctuations in body and responds to changing blood glucose levels. The lower or higher blood sugar levels are lead to release of more or less insulin, respectively. Smart insulin decreases the number of regular blood tests required and also minimizes the number of daily dose of insulin injections. Researchers from the University of North Carolina have been working on a smart insulin patch. For instance, in 2015, researchers reported that, smart insulin patch can use a micro-needles system to automatically detect high blood glucose levels and administer insulin appropriately.

To get holistic SAMPLE of the report including table of contents: https://www.coherentmarketinsights.com/insight/request-sample/1797

Key players in the human recombinant insulin market are implementing inorganic growth strategies to develop and introduce smart insulin technology in the market. For instance, in February 2016, Eli Lilly and Company acquired Glycostasis, Inc., a startup company engaged in developing smart insulin. Eli Lilly and Company is focused on developing Glycostasis’s ‘smart insulin’ technology.

Key takeaways of the Human Recombinant Insulin Market:

• The global human recombinant insulin market is expected to expand at a CAGR of 7.2% during the forecast period (2018 – 2026), owing to increasing technological advancement in recombinant human insulin by various key players.
• Long acting human insulin are projected to grow with higher pace during the forecasted period in the product type segment, owing to their higher efficiency and ability to offer consistent insulin delivery throughout the day, lasting 24 hours.
• Other brands hold major market share in brand segment, due to the involvement of innovative and new human recombinant insulin portfolio with increased patent expiry period such as Toujeo, Tresiba, Basaglar, among others; in this segment, which further expected to capture higher market share, during the forecast period.
• Retail pharmacies holds largest market share in distribution channel segment. As retail pharmacies offer direct access to full range of diabetes products, covering all prescription and over-the-counter products for patients with diabetes.
• Some of the major players operating in global human recombinant insulin market include Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Julphar Gulf Pharmaceutical Industries, Biocon Limited, Bioton S.A., Gan & Lee Pharmaceuticals, Ltd., Zhuhai United Laboratories Co., Ltd., Wanbang Biopharmaceuticals Co., Ltd. and Dongbao Enterprise Group Co., Ltd.

About CMI

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Fallopian Tube Cancer Market: Drivers, Regional Analysis, and Competitive Landscape 2026

Cells in the body divide and grow to replace damaged and old cells. Cell growth is highly regulated and when sufficient amount of cells are produced to replace the old ones, the division of normal cells is stopped. Regulation error in the cell division process can cause cells to continually divide in an uncontrollable manner, which leads to the development of tumor. Fallopian tubes are also known as oviducts, which are a pair of narrow tubes that transport ova (eggs) to the uterus. Abnormal growth of malignant cells in one or both fallopian tubes in women can cause fallopian tube cancer. Majority of fallopian tube cancer are of papillary serous adenocarcinomas type, the other two types of fallopian tube cancer are very rare such as sarcoma, which affects the muscular part of the fallopian tube and transitional cell found in the fallopian tube lining, and metastasis that spreads cancer cells to other parts of the body. The symptoms of ovarian cancer are similar to that of fallopian tube cancer, which include abdominal pain, watery discharge that may contain blood, vaginal bleeding, and swollen abdomen. Tests for diagnosis of fallopian tube cancer include CA125 blood test, pelvic exam, ultrasound, and CT scan. Some of the recommended treatment options for fallopian tube cancer are open surgery treatment, which involves the removal of the uterus through an incision in the abdomen and chemotherapy treatment, using drugs to kill cancer cells, which may be prescribed pre- and post-surgery.

Click to Continue Reading on Fallopian Tube Cancer Market

Fallopian Tube Cancer Market Dynamics

Increasing development of treatments is expected to boost growth of the fallopian tube cancer market. For instance, In 2018 Rucaparib, a poly ADP-ribose polymerase (PARP) inhibitor, developed by Clovis Oncology Inc. received FDA approval for the maintenance treatment of recurrent fallopian tube cancer, ovarian cancer or primary peritoneal cancer. Moreover, increasing prevalence of cancer-related diseases and genetic disorders are factors responsible for fallopian tube cancer market growth. According to 2018 statistics by the Foundation for Women’s Cancer, around 32,120 women are projected to die from gynecologic cancer diseases and 110,070 women are projected to be diagnosed with a gynecologic cancer in 2018. According to the American Society of Clinical Oncology, in the U.S., around 22,240 cases of ovarian cancer were diagnosed in 2017.

Major challenges faced by the fallopian tube cancer market players include high treatment costs, and side effects associated with the chemotherapy treatment such as fatigue, hair loss, and nausea are expected to hinder the market growth. For instance, according to published article in Journal of the National Comprehensive Network 2016, the mean total payment per patient in the initial treatment period of ovarian cancer was US$ 65,908.

Fallopian Tube Cancer Market – Regional Insights

On the basis of geography, the global fallopian tube cancer market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America fallopian tube cancer market holds a dominant position on account of increasing number of fallopian tube cancer cases and high R&D investment from government organization for the prevention of cancer-related diseases in the region. For instance, according to the National Cancer Institute in 2016 fiscal year report, around US$ 95,587,126 was funded for ovarian cancer research alone. Asia Pacific is considered as the emerging market in the global fallopian tube cancer market. Rising incidence of fallopian cancer in Asia Pacific is expected to be a major factor of growth for this region, supported by growing awareness among the population. For instance, according to a published article in 2015 Chinese Journal of Cancer Research, showed around 45,223 new ovary cancer cases, accounting for 3.11% of all new female cancer cases in China in 2011.

To get holistic SAMPLE of the report including table of contents: https://www.coherentmarketinsights.com/insight/request-sample/1826

Fallopian Tube Cancer Market – Competitive Landscape

Major players operating in the global fallopian tube cancer market include Roche, Tesaro, Clovis Oncology, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Amgen Inc., Eli Lilly and Company, GlaxoSmithKline plc, AstraZeneca plc, and F. Hoffmann-La Roche Ltd. Major players are engaged in developing advanced products for fallopian tube cancer treatment and are focusing on collaborations, in order to retain their foothold in the global market. For Instance, in 2017, Merck & Co., Inc. and AstraZeneca enrolled a global strategic oncology collaboration to co-commercialize and co-develop AstraZeneca’s Lynparza for multiple cancer types. Lynparza, an innovative, top-tier oral poly ADP ribose polymerase (PARP) inhibitor, is approved in 2014 for BRCA1 gene mutated ovarian cancer in multiple line of treatment.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Medical Radiation Detection, Monitoring, and Safety Market: Drivers, Regional Analysis, And Competitive Landscape 2026

Radiation power is used in various fields such as industries, agriculture, and medicine to benefit humankind. It is widely being used in modern medical treatments, especially for the treatment of cancer, as radiation helps in weakening and destroying particular cancer cells. Modern medicine uses radiation power to obtain diagnostic information about a patient’s specific organ for treatment. Medical imaging helps in diagnosing and detection of diseases at early stages. For instance, exploratory cardiac catheterization is replaced with CT scan for the detection of polyp in the body, which can turn cancerous if it is not detected at the early stage. Medical radiation detection, monitoring, and safety market is segmented into detector type, monitoring products, and safety products. Various types of detectors include solid-state detectors, liquid filled detectors, and scintillators. Solid-state detectors, which provides good accuracy and reproducibility, are used to perform in vivo dosimetry and quality control for both radiotherapy and radiology.

Request a sample to stay abreast on the key trends impacting this market: https://www.coherentmarketinsights.com/insight/request-sample/1802

Medical Radiation Detection, Monitoring, and Safety Market: Drivers

Increasing use of radiation therapy for treatment and diagnosis purposes is expected to fuel growth of medical radiation detection, monitoring, and safety market. According to a study conducted by the National Academics of Sciences Engineering and Medicine in 2016, over 400 million diagnostic examinations and around150 million dental X-ray examinations were performed in the 2015. Increasing prevalence of cancer, rising awareness about use of radiation therapy to treat diseases, and favorable reimbursement policies are other factors that drive growth of medical radiation detection, monitoring, and safety market. According to a study conducted by the U.S. Department of Health & Human Services in 2016, over 80% people in the U.S. have some form of medical insurance. Mergers and acquisitions adopted by major players are also expected to drive growth of medical radiation detection, monitoring, and safety market. For instance, in 2014, Elekta, a Sweden-based company acquired Medical Resonant Inc., a Canada based company. Through this acquisition, Elekta added new solutions for image guidance and R&D resources in the field of oncology imaging to their product portfolio. Moreover, innovations in the field of radiation therapy is expected to boost growth of medical radiation detection, monitoring, and safety market. For instance, in 2017, QFix, a U.S.-based company launched Access 360 G2 and Access Prone G2, a radiotherapy positioning technology for precise treatment of breast cancer. These devices reduce radiation dose to a healthy tissue while improving patient comfort.

However, lack of skilled technicians to use radiation therapy devices and high cost of radiation therapy devices are factors that hamper growth of the market.

Medical Radiation Detection, Monitoring, and Safety Market: Regional Analysis

North America is expected to witness significant growth in the medical radiation detection, monitoring, and safety market over the forecast period due to new innovations in radiation therapy in the region. For instance, in April 2018, Varian Medical Systems, a U.S.-based company launched 4.0 velocity cancer imaging software with selective internal radiation therapy dosimetry analysis. This software includes Rapidsphere, a module used for Selective Internal Radiation Therapy (SIRT) dosimetry analysis. Rapidsphere provides the ability to understand tumor response and normal tissue toxicity for individual patients receiving SIRT.

Asia Pacific is expected to witness significant growth in the medical radiation detection, monitoring, and safety market over the forecast period due to reimbursement policies made by the government. For instance, the Central Government Health Scheme in India has taken initiative to reimburse medical expenses within 6 months of treatment of diseases such as cancer and cardiovascular diseases. Furthermore, Europe is expected to witness growth in the market due to high prevalence of cancer. According to a study conducted by the European Cancer Organisation, in 2017, over 1.7 billion people were diagnosed with cancer, out of which around 20% of the people died due to late treatment and diagnosis.

Click To Continue Reading on Medical Radiation Detection, Monitoring, and Safety Market

Medical Radiation Detection, Monitoring, and Safety Market: Competitive Landscape

Key players operating in the medical radiation detection, monitoring, and safety market include Thermo Fisher Scientific Inc., Canberra Industries Inc., Bar-Ray products Inc., Protech Radiation Safety, ProtecX, Landauer Inc., Mirion Technologies Inc., Amtech Inc., and Biodex Medical Inc.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Peptide Therapeutics Market to surpass US$ 45.0 billion by 2026: CMI

The Global Peptide Therapeutics Market, by Type (Branded Peptide and Generic Peptide), by Application (Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease, and Others), By Route of Administration (Oral Administration, Parenteral Administration, and Others), was valued US$ 22.5 billion in 2018, and is projected to exhibit a CAGR of 9.1% over the forecast period (2018 - 2026) as highlighted in a new report published by Coherent Market Insights.

Peptide therapeutics have wide range of applications in medicine and biotechnology and therapeutic peptide research field. Peptide therapeutics are majorly used in the cancer treatment and type 2 diabetes mellitus (T2DM) treatment. According to the Drug Discovery Today, January 2015 data findings, novel peptide drug class: glucagon-like peptide-1 (GLP-1) agonists; indicated for the treatment of type 2 diabetes mellitus (T2DM), shows lucrative market growth, as Victoza from Novo Nordisk, is the most prominent member of the class, reaching blockbuster status. Moreover, main area currently driving the growth of peptide therapeutics drugs adoption are metabolic diseases and cancer treatment. Furthermore, peptide therapeutics are in clinical testing for infectious diseases and inflammation.

Request a sample to stay abreast on the key trends impacting this market: https://www.coherentmarketinsights.com/insight/request-sample/1837

Key players in the peptide therapeutic market are engaged in expanding market share through new product launches and regulatory approval. For instance, in March 2016, Eli Lilly and Company introduced anti-diabetes drug Trulicity (dulaglutide) in India. Trulicity (dulaglutide) is once-a- week non-insulin injectable belonging to class of drugs called glucagon-like peptide (GLP-1) receptor agonist, which helps the body to release its own insulin after the intake of food. In July 2016, U.S. Food and Drug Administration (FDA), approved Sanofi-Aventis’s Adlyxin (lixisenatide), a once-daily injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with type 2 diabetes.

Peptide therapeutics market is projected to witness lucrative growth over the forecast period, owing to the various in-organic growth strategies implemented by key manufacturing players in this market. For instance, in July 2012, Amgen Inc. completed the acquisition of KAI Pharmaceuticals, Inc. for a deal value of US$ 315 million. During the acquisition, KAI Pharmaceuticals had a peptide product in development stage: KAI-4169, which is indicated for the treatment of Secondary Hyperparathyroidism (SHPT) in patients with Chronic Kidney Disease (CKD) who are on dialysis and is in currently in phase 2 trials. Moreover, this acquisition allowed Amgen to acquire worldwide rights of KAI-4169, excluding Japan.

Furthermore, in September 2015, PeptiDream Inc. developed a multi-target discovery and optimization collaboration with Sanofi S.A. Under this agreement, PeptiDream will use their proprietary Peptide Discovery Platform System (PDPS) technology to generate macrocyclic/constrained peptides against multiple targets of interest selected by Sanofi S.A. Furthermore, Sanofi will have the right to develop and commercialize all therapeutic peptides resulting from the collaboration.

Browse 26 Market Data Tables and 45 Figures spread through 189 Pages and in-depth TOC on "Peptide Therapeutics Market, by Type (Branded Peptide and Generic Peptide), by Application (Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Others), By Route of Administration (Oral Administration, Parenteral Administration, and Others) - Global Forecast to 2026"

To know the latest trends and insights related to peptide therapeutics market, click the link below: https://www.coherentmarketinsights.com/market-insight/peptide-therapeutics-market-1837

In December 2017, Entrega collaborated with Eli Lilly and Company to make advancement in Entrega’s proprietary peptide delivery technology. Under the agreement, Entrega will receive the US$ 5 million in equity and research in funding from Eli Lilly to investigate the application of Entrega’s peptide delivery technology to certain Lilly products and their therapeutic candidates.

Key takeaways of the Peptide Therapeutics Market:

• The global peptide therapeutics market is expected to expand at a CAGR of 9.1% during the forecast period (2018 – 2026), owing to increasing technological advancement in peptide therapeutics by various key players.
• Among type segment, branded therapeutic peptide is expected to witness significant growth in peptide therapeutics market, owing to increasing investment by various key manufacturers in research and development (R&D) for the development of branded or innovative peptide drugs and high prescription rate.
• Cancer holds major market share in application segment due to increasing prevalence and incidence among global population. In addition, increasing adoption of peptide therapeutics in cancer treatment, growing awareness among the patients and healthcare professionals regarding adverse effects of chemotherapy and growing need towards alternative therapeutics such as peptide-based drugs, will further drive the cancer segment of peptide therapeutics market.
• Parenteral administration holds largest market share in route of administration segment, owing to easy and increased absorption of peptide drugs into the patient’s body. According to the Drug Discovery Today, January 2015 data findings, majority (75%) of the peptide drugs are administrated by parenteral route.
• Some of the major players operating in global peptide therapeutics market include Teva Pharmaceutical Industries Ltd., Takeda Pharmaceuticals Co. Ltd., Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Encycle Therapeutics, Inc., CirclePharma, Inc., Pfizer Inc., Novartis AG, PeptiDream Inc., and Amgen Inc.

About CMI

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Endocrine Testing Market - Latest Advancements & Market Outlook 2018 to 2026

The Global Endocrine Testing Market, by Test (Thyroid, Insulin, Follicle Stimulating Hormone, Luteinizing, Hormone, Estradiol, Testosterone, Progesterone, Human chorionic gonadotropin, Prolactin, Cortisol DHEA-S, and Others), by Diagnostic Technology (Immunoassay, Tandem Mass Spectroscopy, Monoclonal and Polyclonal Antibody, Sensor Technologies, Clinical Chemistry, and Others), by End User (Hospitals, Diagnostic Laboratories, and others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 2.95 billion in 2017 and is projected to exhibit a CAGR of 4.9% over the forecast period (2018 – 2026), as highlighted in a new report published by Coherent Market Insights.

Browse 45 Market Data Tables and 35 Figures spread through 200 Pages and in-depth TOC on “Endocrine Testing Market - by Test (Thyroid, Insulin, Follicle Stimulating Hormone, Luteinizing, Hormone, Estradiol, Testosterone, Progesterone, Human chorionic gonadotropin, Prolactin, Cortisol DHEA-S and Others), by Diagnostic Technology (Immunoassay, Tandem Mass Spectroscopy, Monoclonal and Polyclonal Antibody, Sensor Technologies, Clinical Chemistry, and Others), by End User (Hospitals, Diagnostic Laboratories and others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Global forecast to 2026”

To know the latest trends and insights prevalent in the endocrine testing market, click the link below: https://www.coherentmarketinsights.com/market-insight/endocrine-testing-market-1755

Endocrine testing allows profiling of blood concentration of the various endocrine hormone. Over secretion and under secretion of endocrinal hormones results in to development of endocrinal disease. Various endocrinal disease such as hypothyroidism, hyperthyroidism, infertility, polycystic ovarian syndrome, hypo/hyperadrenocorticism, hypogonadism, diabetes, Multiple endocrine neoplasia I and II, Cushing’s disease, Gigantism (acromegaly) and other growth hormone problem and precocious puberty( Early Puberty). Endocrine diseases are caused due to various reasons such as problem in endocrine feedback system, disease condition, and failure of stimulation of glands to release hormones, tumor of an endocrine gland, genetic disorders, infection and physical trauma to an endocrine gland. Increasing prevalence of these disease especially hypothyroidism, infertility, and diabetes are expected to drive growth of the global endocrinal testing market. According to study published by Centre for Disease Control and Prevention (CDC), in 2017, around 100 million (30.3 million diabetes and 84.1 million prediabetes) U.S. adults were suffering from diabetes or prediabetes condition. According to American Thyroid Association, 2017, around 12% of U.S. adults are estimated to develop thyroid disease in their lifetime. Postmenopausal osteoporosis caused due to reduced estrogen production after menopause leading to low bone mineral density and increased risk for fracture risks. It is estimated that osteoporosis affects around 10 million American adults annually, 34 million people are at high risk of it due to low bone mass, according to study published by BMC Endocrine Disorder in February 2018.

Key players are undergoing strategic mergers, acquisitions, and collaborations in order to maintain leading position in market and to tap the new market. In August 2017, North West London Pathology under National Health Service Trust and Abbott Laboratories signed contract worth US$ 252 million under which Abbott Laboratories will supply all analytical equipment and consumables, this contract would manage 26 million tests annually. In 2017, Abbott Laboratories received the U.S. Food and Drug Administration (FDA) 510(k) clearance for its Alinity ci-series instruments for clinical chemistry and immunoassay diagnostics. In April 2018, Beckman Coulter launched its Access Sensitive Estradiol assay in the U.S. market, also made available its assay in the most of global markets. This test accurately detects estradiol levels in women, children, and men using low sample. Company also launched Anti-Müllerian Hormone (AMH) assay in 2017, which helps in clinical management of women suffering from infertility. In 2016, company received FDA clearance and commercially launched new Access TSH (3rd IS) assay.

To get holistic SAMPLE of the report including table of contents: https://www.coherentmarketinsights.com/insight/request-sample/1755

Key Takeaways of the Endocrine Testing Market:

• The global endocrine testing market is expected to exhibit a CAGR of 4.9% over the forecast period, owing to increasing prevalence of endocrine disease and need for their early diagnosis.
• Among test type, thyroid test segment is expected to hold a dominant position in market during the forecast period due to increasing number of thyroid disorders and its high prevalence. Thyroid test would be followed by fertility related hormone testing (FSH, Progesterone etc.) due to high incidence if infertility throughout globe. Amongst diagnostic technology segment, tandem mass spectroscopy would gain maximum share due to high accuracy and short time to detect the analyte in sample, amongst end user hospitals would prevail over other end user.
• North America region is expected to hold dominant position in the global endocrine testing market, followed by Europe and Asia Pacific. The U.S. has high prevalence of endocrine disease such as hypo/hyperthyroidism. For instance, According to American Thyroid Association, in 2017, around 60% of people suffering from thyroid disease are unaware of their disease. Europe region is expected to witness growth in endocrine testing market, owing to increasing number of population age 65 and above. According to European statistics 2017, around 19% of European population was 65 and above in 2016. Emerging economies from Asia Pacific region are expected to present potential opportunity as this region is facing increasing number in endocrine disorder.
• Key players operating in the endocrine testing market include Abbott Laboratories, Thermo Fisher Scientific, Beckman Coulter, Inc., Siemens Healthineers, bioMérieux SA, Agilent Technologies, Bi-Rad Laboratories, AB Sciex, F-Hoffmann La Roche AG, Quest Diagnostics, and others

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.